Form 4: Director Michael Paolucci Receives Orthofix Stock Award

Director Michael E. Paolucci was granted 14,965 deferred stock units by Orthofix Medical Inc. as part of an equity award.

Summary

• Director Michael E. Paolucci acquired 14,965 deferred stock units (DSUs) on June 10, 2026.
• The award was granted at a price of $0 per share, representing a contingent right to receive common stock.
• Following this transaction, the director's total beneficial ownership increased to 102,727 shares.
• The DSUs vest in full on the first anniversary of the grant date, contingent upon continued service.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation with no material impact on company operations or financial outlook.

Positives

• The director's increased equity stake aligns his interests with those of shareholders.
• The grant reflects ongoing commitment to the company through long-term equity incentives.

Negatives

• None identified; this is a standard equity compensation disclosure.

Risks

• Vesting is subject to the director's continued service through the first anniversary of the grant date.

Future Outlook

The deferred stock units will vest on June 10, 2027, and will settle into common stock within 45 days of the director's eventual termination of service.

Industry Context

StockSavvy.ai notes that equity-based compensation for board members is a standard practice in the medical device industry to ensure long-term alignment between governance and shareholder value.

Comparison to Industry Standards

• The use of deferred stock units as a retention and alignment tool is consistent with standard corporate governance practices for mid-cap medical technology companies.
• The vesting schedule of one year is typical for non-employee director equity grants.

Stakeholder Impact

• Shareholders benefit from the increased alignment of the director's financial interests with the company's long-term performance.

Next Steps

• Vesting of the 14,965 deferred stock units on June 10, 2027.

Key Dates

Keywords

Orthofix Medical, OFIX, Form 4, Insider Trading, Director Compensation, Equity Award